Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.39
RHHBY's Cash to Debt is ranked lower than
88% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. RHHBY: 0.39 )
Ranked among companies with meaningful Cash to Debt only.
RHHBY' s Cash to Debt Range Over the Past 10 Years
Min: 0.36  Med: 1.51 Max: N/A
Current: 0.39
Equity to Asset 0.28
RHHBY's Equity to Asset is ranked lower than
84% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RHHBY: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
RHHBY' s Equity to Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.35 Max: 0.59
Current: 0.28
0.1
0.59
Interest Coverage 15.96
RHHBY's Interest Coverage is ranked lower than
86% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RHHBY: 15.96 )
Ranked among companies with meaningful Interest Coverage only.
RHHBY' s Interest Coverage Range Over the Past 10 Years
Min: 15.22  Med: 15.96 Max: 65.07
Current: 15.96
15.22
65.07
F-Score: 5
Z-Score: 3.56
M-Score: -2.86
WACC vs ROIC
8.05%
30.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 27.42
RHHBY's Operating margin (%) is ranked higher than
89% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. RHHBY: 27.42 )
Ranked among companies with meaningful Operating margin (%) only.
RHHBY' s Operating margin (%) Range Over the Past 10 Years
Min: 25.03  Med: 29.07 Max: 33.69
Current: 27.42
25.03
33.69
Net-margin (%) 17.58
RHHBY's Net-margin (%) is ranked higher than
86% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. RHHBY: 17.58 )
Ranked among companies with meaningful Net-margin (%) only.
RHHBY' s Net-margin (%) Range Over the Past 10 Years
Min: 15.87  Med: 18.72 Max: 22.97
Current: 17.58
15.87
22.97
ROE (%) 46.10
RHHBY's ROE (%) is ranked higher than
98% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. RHHBY: 46.10 )
Ranked among companies with meaningful ROE (%) only.
RHHBY' s ROE (%) Range Over the Past 10 Years
Min: 19.94  Med: 48.00 Max: 102.95
Current: 46.1
19.94
102.95
ROA (%) 12.07
RHHBY's ROA (%) is ranked higher than
91% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. RHHBY: 12.07 )
Ranked among companies with meaningful ROA (%) only.
RHHBY' s ROA (%) Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 12.07
10.33
17.58
ROC (Joel Greenblatt) (%) 64.53
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. RHHBY: 64.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RHHBY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 52.39  Med: 64.70 Max: 84.52
Current: 64.53
52.39
84.52
Revenue Growth (3Y)(%) 3.20
RHHBY's Revenue Growth (3Y)(%) is ranked higher than
53% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. RHHBY: 3.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RHHBY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.20 Max: 391.7
Current: 3.2
0
391.7
EBITDA Growth (3Y)(%) -0.40
RHHBY's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. RHHBY: -0.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RHHBY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.70 Max: 280
Current: -0.4
0
280
EPS Growth (3Y)(%) -2.30
RHHBY's EPS Growth (3Y)(%) is ranked higher than
53% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. RHHBY: -2.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RHHBY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.40 Max: 338
Current: -2.3
0
338
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

RHHBY Guru Trades in Q1 2015

Mairs and Power 2,703,876 sh (+3.62%)
Ken Fisher 2,788,126 sh (-1.24%)
» More
Q2 2015

RHHBY Guru Trades in Q2 2015

Ken Fisher 14,211,412 sh (+409.71%)
Mairs and Power 2,712,376 sh (+0.31%)
» More
Q3 2015

RHHBY Guru Trades in Q3 2015

Ken Fisher 14,538,602 sh (+2.30%)
Mairs and Power 2,712,985 sh (+0.02%)
» More
Q4 2015

RHHBY Guru Trades in Q4 2015

Ken Fisher 14,630,453 sh (+0.63%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Roche Holding AG

Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Largest trades in second quarter include also Infosys and Alibaba
Ken Fisher (Trades, Portfolio) is the chief executive officer and chief investment officer of Fisher Investments, which offers an array of educational resources to its 27,000-plus private clients —including quarterly reports, in-person seminars and regular phone communication. Fisher Investments extends these educational resources to the public through a series of investing guides, online videos and daily commentary at MarketMinder.com. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.60
RHHBY's P/E(ttm) is ranked higher than
59% of the 390 Companies
in the Global Biotechnology industry.

( Industry Median: 26.50 vs. RHHBY: 23.60 )
Ranked among companies with meaningful P/E(ttm) only.
RHHBY' s P/E(ttm) Range Over the Past 10 Years
Min: 13.05  Med: 18.15 Max: 26.92
Current: 23.6
13.05
26.92
Forward P/E 15.48
RHHBY's Forward P/E is ranked higher than
57% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 16.50 vs. RHHBY: 15.48 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.60
RHHBY's PE(NRI) is ranked higher than
63% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. RHHBY: 23.60 )
Ranked among companies with meaningful PE(NRI) only.
RHHBY' s PE(NRI) Range Over the Past 10 Years
Min: 13.04  Med: 17.86 Max: 26.92
Current: 23.6
13.04
26.92
P/B 9.87
RHHBY's P/B is ranked lower than
99.99% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. RHHBY: 9.87 )
Ranked among companies with meaningful P/B only.
RHHBY' s P/B Range Over the Past 10 Years
Min: 2.64  Med: 11.81 Max: 22.21
Current: 9.87
2.64
22.21
P/S 4.16
RHHBY's P/S is ranked higher than
72% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. RHHBY: 4.16 )
Ranked among companies with meaningful P/S only.
RHHBY' s P/S Range Over the Past 10 Years
Min: 2.38  Med: 3.54 Max: 5.04
Current: 4.16
2.38
5.04
PFCF 18.81
RHHBY's PFCF is ranked higher than
65% of the 269 Companies
in the Global Biotechnology industry.

( Industry Median: 27.55 vs. RHHBY: 18.81 )
Ranked among companies with meaningful PFCF only.
RHHBY' s PFCF Range Over the Past 10 Years
Min: 8.6  Med: 16.17 Max: 26.6
Current: 18.81
8.6
26.6
POCF 13.74
RHHBY's POCF is ranked higher than
71% of the 395 Companies
in the Global Biotechnology industry.

( Industry Median: 27.92 vs. RHHBY: 13.74 )
Ranked among companies with meaningful POCF only.
RHHBY' s POCF Range Over the Past 10 Years
Min: 6.98  Med: 12.27 Max: 16.48
Current: 13.74
6.98
16.48
EV-to-EBIT 16.91
RHHBY's EV-to-EBIT is ranked higher than
56% of the 452 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. RHHBY: 16.91 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHBY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.6  Med: 12.50 Max: 19.4
Current: 16.91
7.6
19.4
EV-to-EBITDA 13.17
RHHBY's EV-to-EBITDA is ranked higher than
59% of the 479 Companies
in the Global Biotechnology industry.

( Industry Median: 15.17 vs. RHHBY: 13.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHBY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 10.50 Max: 15.3
Current: 13.17
6.4
15.3
PEG 19.67
RHHBY's PEG is ranked lower than
88% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. RHHBY: 19.67 )
Ranked among companies with meaningful PEG only.
RHHBY' s PEG Range Over the Past 10 Years
Min: 0.23  Med: 4.54 Max: 23.01
Current: 19.67
0.23
23.01
Shiller P/E 21.49
RHHBY's Shiller P/E is ranked higher than
88% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 47.95 vs. RHHBY: 21.49 )
Ranked among companies with meaningful Shiller P/E only.
RHHBY' s Shiller P/E Range Over the Past 10 Years
Min: 19.25  Med: 24.10 Max: 38.09
Current: 21.49
19.25
38.09
Current Ratio 1.19
RHHBY's Current Ratio is ranked lower than
86% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. RHHBY: 1.19 )
Ranked among companies with meaningful Current Ratio only.
RHHBY' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 2.37 Max: 3.75
Current: 1.19
1.19
3.75
Quick Ratio 0.86
RHHBY's Quick Ratio is ranked lower than
87% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. RHHBY: 0.86 )
Ranked among companies with meaningful Quick Ratio only.
RHHBY' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.97 Max: 3.22
Current: 0.86
0.86
3.22
Days Inventory 179.07
RHHBY's Days Inventory is ranked lower than
66% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. RHHBY: 179.07 )
Ranked among companies with meaningful Days Inventory only.
RHHBY' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 158.92 Max: 186.16
Current: 179.07
143.33
186.16
Days Sales Outstanding 60.32
RHHBY's Days Sales Outstanding is ranked higher than
54% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. RHHBY: 60.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.32  Med: 73.97 Max: 84.09
Current: 60.32
60.32
84.09
Days Payable 75.72
RHHBY's Days Payable is ranked higher than
59% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. RHHBY: 75.72 )
Ranked among companies with meaningful Days Payable only.
RHHBY' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 58.31 Max: 78.64
Current: 75.72
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.21
RHHBY's Dividend Yield is ranked higher than
88% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. RHHBY: 3.21 )
Ranked among companies with meaningful Dividend Yield only.
RHHBY' s Dividend Yield Range Over the Past 10 Years
Min: 1.51  Med: 2.94 Max: 4.55
Current: 3.21
1.51
4.55
Dividend Payout 0.74
RHHBY's Dividend Payout is ranked lower than
81% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. RHHBY: 0.74 )
Ranked among companies with meaningful Dividend Payout only.
RHHBY' s Dividend Payout Range Over the Past 10 Years
Min: 0.21  Med: 0.56 Max: 0.78
Current: 0.74
0.21
0.78
Dividend Growth (3y) 5.60
RHHBY's Dividend Growth (3y) is ranked higher than
53% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. RHHBY: 5.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
RHHBY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 5.70 Max: 27.3
Current: 5.6
0
27.3
Forward Dividend Yield 3.30
RHHBY's Forward Dividend Yield is ranked higher than
86% of the 217 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. RHHBY: 3.30 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.28
RHHBY's Yield on cost (5-Year) is ranked higher than
86% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. RHHBY: 4.28 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RHHBY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.01  Med: 3.92 Max: 6.06
Current: 4.28
2.01
6.06
3-Year Average Share Buyback Ratio -0.30
RHHBY's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: -9.90 vs. RHHBY: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHBY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: 0.00 Max: 78.7
Current: -0.3
-0.8
78.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.62
RHHBY's Price/Projected FCF is ranked higher than
77% of the 283 Companies
in the Global Biotechnology industry.

( Industry Median: 2.87 vs. RHHBY: 1.62 )
Ranked among companies with meaningful Price/Projected FCF only.
RHHBY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.32  Med: 1.84 Max: 7.13
Current: 1.62
1.32
7.13
Price/Median PS Value 1.18
RHHBY's Price/Median PS Value is ranked lower than
57% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. RHHBY: 1.18 )
Ranked among companies with meaningful Price/Median PS Value only.
RHHBY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.73  Med: 1.11 Max: 1.41
Current: 1.18
0.73
1.41
Earnings Yield (Greenblatt) (%) 5.90
RHHBY's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. RHHBY: 5.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RHHBY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.2  Med: 8.00 Max: 13.2
Current: 5.9
5.2
13.2
Forward Rate of Return (Yacktman) (%) 6.87
RHHBY's Forward Rate of Return (Yacktman) (%) is ranked lower than
60% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. RHHBY: 6.87 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RHHBY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.3  Med: 8.90 Max: 62.9
Current: 6.87
4.3
62.9

More Statistics

Revenue(Mil) $50912
EPS $ 1.30
Beta0.72
Short Percentage of Float0.00%
52-Week Range $30.85 - 38.54
Shares Outstanding(Mil)6816.16

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 42,907 45,840 46,186
EPS($) 1.54 1.64 1.77
EPS without NRI($) 1.54 1.64 1.77

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience. It has more than 66 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals and Chugai, whereas Genentech as the former third segment has been integrated into Roche Pharmaceuticals. The Diagnostics Division consists of the following four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Invesco European Growth Fund Adds to 7 Stakes Jan 26 2016 
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Roche’s Oncology Drugs Drive Its Revenue Northwards In Q1 Apr 24 2015 
Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 

More From Other Websites
Roche to Stop Study on Lung Cancer Drug Alecensa Early Feb 11 2016
Latest developments in cancer research and treatment explored by top global scientists at Tucson... Feb 08 2016
Roche Holding AG Earnings Analysis: 2015 By the Numbers Feb 05 2016
ROCHE HOLDING LTD /FI Financials Feb 04 2016
Pacific Biosciences (PACB) Jumps: Stock Moves Up 24.3% Feb 03 2016
Roche eyes acquisition of Pacific Biosciences-sources Feb 02 2016
Roche's Stock May Have Been Down, But The Company's Business Has Strong Outlook Feb 02 2016
Updated cervical cancer screening guidelines from leading ob-gyn society support expanded use of... Feb 01 2016
Roche's (RHHBY) Earnings Miss Estimates, Revenues Beat Jan 29 2016
Roche annual profit disappoints, outlook muted Jan 28 2016
Roche annual profit disappoints, outlook muted Jan 28 2016
Roche annual profit disappoints, outlook muted Jan 28 2016
European shares fall, hit by weak earnings and banks Jan 28 2016
European shares fall, hit by weak earnings and banks Jan 28 2016
[$$] Roche Profit Dented by Strong Swiss Franc Jan 28 2016
European shares down in choppy trade led by Roche; oils up Jan 28 2016
Roche earnings fall short of forecasts Jan 28 2016
Roche Falls After Full-Year Profit Misses Analyst Estimates Jan 28 2016
Coverage initiated on Roche Hldg by Piper Jaffray Jan 22 2016
Roche/AbbVie's Leukemia Drug Gets Breakthrough Status Jan 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK